Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colourbridge: rAAV.hCNGA3 for CNGA3-linked Achromatopsia
NCT02610582Phase 2Active, not recruiting
- Sponsor
- STZ eyetrial
- Start
- Nov 2015
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of rAAV.hCNGA3 in achromatopsia (ACHM), sponsored by STZ eyetrial. Started Nov 2015; status: active, not recruiting.
02
Drugs
rAAV.hCNGA3
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on NCT02610582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610582.